Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-008799Source: DataRank Database

Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 3.85)OA: goldTopics (29)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Ethan C. Hill ORCID,Jena E. Moseman ORCID,Douglas G. McNeel ORCID,Donghwan Jeon

Live enrichment

PubMed:38702146 PMC:PMC11086196 OpenAlex:https://openalex.org/W4396626215

NIH

Grant: P30 CA014520

NIH

Grant: P50 CA269011

NCI NIH HHS

Grant: T32 CA009135

FWCI

3.85

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://doi.org/10.1136/jitc-2024-008799

publisherhttps://doi.org/10.1136/jitc-2024-008799

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2024-008799

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38702146

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11086196

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research

MeSH Terms

Immune Checkpoint InhibitorsToll-Like Receptor AgonistsAnimalsFemaleHumansCancer VaccinesCell Line, TumorToll-Like ReceptorsMice

Keywords

TLR3Immune systemToll-like receptorCD8ImmunologyMedicineCancer researchImmunotherapyT cellImmune checkpointPharmacologyInnate immune systemVaccineprostate cancerImmune Checkpoint InhibitorT Regulatory Cell - TregToll-like Receptor - Tlr

Sustainable Development Goals

SDG 0: Good health and well-being